This might be explained by our current results specifically identifying TGFBR2 as the driver of GSC-derived induced Treg-like cells and associating their immunosuppressive signature with TGFBR2 but not TGFBR1 expression in clinical specimens across multiple cancers, uncovering previously unrecognized TGFBR2 dependencies in cancer (Figure 3K,N). This evidence concerns the gene TGFBR2 and cancer.